Nasal continuous positive airway pressure outperforms heated high-flow nasal cannula therapy as primary respiratory therapy in preterm infants

Commentary on: Roberts CT, Owen LS, Manley BJ, et al. Nasal high-flow therapy for primary respiratory support in preterm infants. N Engl J Med 2016;375:1142–51.[OpenUrl][1][PubMed][2] High-flow nasal cannula (HFNC) therapy for preterm newborn infants has quickly gained popularity,1 despite few studies evaluating the underlying mechanisms and lack of high-quality studies evaluating its efficacy.2 Our recent systematic review and meta-analysis,3 and the Cochrane review4 suggested that HFNC therapy was comparable in efficacy to continuous positive airway pressure (CPAP) as a primary mode of support in preterm infants at birth, for respiratory distress syndrome (RDS) in preterm … [1]: {openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D375%26rft.spage%253D1142%26rft_id%253Dinfo%253Apmid%252F27653564%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=27653564&link_type=MED&atom=%2Febmed%2F22%2F2%2F63.atom